The role of midkine in skeletal remodelling

A Liedert; T Schinke; A Ignatius; M Amling

doi:10.1111/bph.12412

The role of midkine in skeletal remodelling

Standard

The role of midkine in skeletal remodelling. / Liedert, A; Schinke, T; Ignatius, A; Amling, M.

In: BRIT J PHARMACOL, Vol. 171, No. 4, 01.02.2014, p. 870-878.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Liedert, A, Schinke, T, Ignatius, A & Amling, M 2014, 'The role of midkine in skeletal remodelling', BRIT J PHARMACOL, vol. 171, no. 4, pp. 870-878. https://doi.org/10.1111/bph.12412

APA

Liedert, A., Schinke, T., Ignatius, A., & Amling, M. (2014). The role of midkine in skeletal remodelling. BRIT J PHARMACOL, 171(4), 870-878. https://doi.org/10.1111/bph.12412

Vancouver

Liedert A, Schinke T, Ignatius A, Amling M. The role of midkine in skeletal remodelling. BRIT J PHARMACOL. 2014 Feb 1;171(4):870-878. https://doi.org/10.1111/bph.12412

Bibtex

@article{78978ec84177454e857f0e7881b7172e,

title = "The role of midkine in skeletal remodelling",

abstract = "UNLABELLED: Bone tissue is subjected to continuous remodelling, replacing old or damaged bone throughout life. In bone remodelling, the coordinated activities of bone-forming osteoblasts and bone-resorbing osteoclasts ensure the maintenance of bone mass and strength. In early life, the balance of these cellular activities is tightly regulated by various factors, including systemic hormones, the mechanical environment and locally released growth factors. Age-related changes in the activity of these factors in bone remodelling can result in diseases with low bone mass, such as osteoporosis. Osteoporosis is a systemic and age-related skeletal disease characterized by low bone mass and structural degeneration of bone tissue, predisposing the patient to an increased fracture risk. The growth factor midkine (Mdk) plays a key role in bone remodelling and it is expressed during bone formation and fracture repair. Using a mouse deficient in Mdk, our group have identified this protein as a negative regulator of bone formation and mechanically induced bone remodelling. Thus, specific Mdk antagonists might represent a therapeutic option for diseases characterized by low bone mass, such as osteoporosis.LINKED ARTICLES: This article is part of a themed section on Midkine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-4.",

keywords = "Animals, Bone Remodeling, Bone and Bones, Carrier Proteins, Cytokines, Humans, Osteoporosis",

author = "A Liedert and T Schinke and A Ignatius and M Amling",

note = "{\textcopyright} 2013 The British Pharmacological Society.",

year = "2014",

month = feb,

day = "1",

doi = "10.1111/bph.12412",

language = "English",

volume = "171",

pages = "870--878",

journal = "BRIT J PHARMACOL",

issn = "0007-1188",

publisher = "Wiley-Blackwell",

number = "4",

}

RIS

TY - JOUR

T1 - The role of midkine in skeletal remodelling

AU - Liedert, A

AU - Schinke, T

AU - Ignatius, A

AU - Amling, M

PY - 2014/2/1

Y1 - 2014/2/1

N2 - UNLABELLED: Bone tissue is subjected to continuous remodelling, replacing old or damaged bone throughout life. In bone remodelling, the coordinated activities of bone-forming osteoblasts and bone-resorbing osteoclasts ensure the maintenance of bone mass and strength. In early life, the balance of these cellular activities is tightly regulated by various factors, including systemic hormones, the mechanical environment and locally released growth factors. Age-related changes in the activity of these factors in bone remodelling can result in diseases with low bone mass, such as osteoporosis. Osteoporosis is a systemic and age-related skeletal disease characterized by low bone mass and structural degeneration of bone tissue, predisposing the patient to an increased fracture risk. The growth factor midkine (Mdk) plays a key role in bone remodelling and it is expressed during bone formation and fracture repair. Using a mouse deficient in Mdk, our group have identified this protein as a negative regulator of bone formation and mechanically induced bone remodelling. Thus, specific Mdk antagonists might represent a therapeutic option for diseases characterized by low bone mass, such as osteoporosis.LINKED ARTICLES: This article is part of a themed section on Midkine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-4.

AB - UNLABELLED: Bone tissue is subjected to continuous remodelling, replacing old or damaged bone throughout life. In bone remodelling, the coordinated activities of bone-forming osteoblasts and bone-resorbing osteoclasts ensure the maintenance of bone mass and strength. In early life, the balance of these cellular activities is tightly regulated by various factors, including systemic hormones, the mechanical environment and locally released growth factors. Age-related changes in the activity of these factors in bone remodelling can result in diseases with low bone mass, such as osteoporosis. Osteoporosis is a systemic and age-related skeletal disease characterized by low bone mass and structural degeneration of bone tissue, predisposing the patient to an increased fracture risk. The growth factor midkine (Mdk) plays a key role in bone remodelling and it is expressed during bone formation and fracture repair. Using a mouse deficient in Mdk, our group have identified this protein as a negative regulator of bone formation and mechanically induced bone remodelling. Thus, specific Mdk antagonists might represent a therapeutic option for diseases characterized by low bone mass, such as osteoporosis.LINKED ARTICLES: This article is part of a themed section on Midkine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-4.

KW - Animals

KW - Bone Remodeling

KW - Bone and Bones

KW - Carrier Proteins

KW - Cytokines

KW - Humans

KW - Osteoporosis

U2 - 10.1111/bph.12412

DO - 10.1111/bph.12412

M3 - SCORING: Journal article

C2 - 24102259

VL - 171

SP - 870

EP - 878

JO - BRIT J PHARMACOL

JF - BRIT J PHARMACOL

SN - 0007-1188

IS - 4

ER -